Drugs.com - New Drug Approvals

FDA Approves Ibtrozi (taletrectinib) for Advanced ROS1-Positive Non-Small Cell Lung Cancer

NEW YORK--(BUSINESS WIRE) June 11, 2025 -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has...

Jun 12, 2025 - 00:20
 0
FDA Approves Ibtrozi (taletrectinib) for Advanced ROS1-Positive Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE) June 11, 2025 -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has...
Read More

Tags:

Previous Article

The Third Way: A New Era Of Beauty Dealmaking Emerges

Next Article

STAT+: Braced for details on Trump’s ‘most favored nation’ policy, pharma indust...

Related Posts

Arcutis’ Zoryve (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

Arcutis’ Zoryve (roflumilast) Topical Foam 0.3% Approve...

May 27, 2025  0

FDA Approves Nuvaxovid (COVID-19 Vaccine, Adjuvanted) to Prevent COVID-19

FDA Approves Nuvaxovid (COVID-19 Vaccine, Adjuvanted) t...

May 21, 2025  0

FDA Approves Mezofy (aripiprazole) Oral Film for the Treatment of Schizophrenia

FDA Approves Mezofy (aripiprazole) Oral Film for the Tr...

May 12, 2025  0